<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases (MAPKs) play an important role in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion (I/R) injury </plain></SENT>
<SENT sid="1" pm="."><plain>Previous evidence suggests that p38 MAPK inhibition before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is cardioprotective </plain></SENT>
<SENT sid="2" pm="."><plain>However, whether p38 MAPK inhibition during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or reperfusion provides cardioprotection is not well known </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the hypothesis that p38 MAPK inhibition at different times during I/R protects the heart from <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, reduces the <z:mpath ids='MPATH_124'>infarct</z:mpath> size, and attenuates ventricular dysfunction </plain></SENT>
<SENT sid="4" pm="."><plain>Adult Wistar rats were subject to a 30-minute left anterior descending coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp>, followed by a 120-minute reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>A p38 MAPK inhibitor, SB203580, was given intravenously before left anterior descending coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp>, during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, or at the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>The results showed that SB203580 given either before or during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but not at the <z:hpo ids='HP_0003674'>onset</z:hpo> of reperfusion, decreased the <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) incidence and heat shock protein 27 phosphorylation, and increased connexin 43 phosphorylation </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> level was decreased in <z:hpo ids='HP_0000001'>all</z:hpo> SB203580-treated rats, without the alteration of the total Bax/Bcl-2 expression </plain></SENT>
<SENT sid="8" pm="."><plain>The ventricular function was improved only in SB203580-pretreated rats </plain></SENT>
<SENT sid="9" pm="."><plain>These findings suggest that timing of p38 MAPK inhibition with respect to <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is an important determinant of therapeutic efficacy </plain></SENT>
</text></document>